

# Raymond L Woosley

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3635065/raymond-l-woosley-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

198  
papers

9,658  
citations

50  
h-index

92  
g-index

215  
ext. papers

10,404  
ext. citations

7.4  
avg, IF

5.84  
L-index

#	Paper	IF	Citations
198	Drug-induced torsades de pointes <b>2022</b> , 39-50		
197	Markers of ventricular repolarization and overall mortality in sleep disordered breathing.. <i>Sleep Medicine</i> , <b>2022</b> , 95, 9-15	4.6	0
196	Assisted prescribing: Clinical decision support with MedSafety Scan now available. <i>Trends in Cardiovascular Medicine</i> , <b>2020</b> , 32, 44-44	6.9	0
195	Identification of populations likely to benefit from pharmacogenomic testing. <i>Pharmacogenetics and Genomics</i> , <b>2020</b> , 30, 91-95	1.9	6
194	Drug-Induced Long QT Syndrome and Torsades de Pointes <b>2020</b> , 185-200		1
193	Investigating the Impact of Gadolinium-Based Contrast Agents on the Corrected QT Interval. <i>Cureus</i> , <b>2020</b> , 12, e9668	1.2	
192	Arrhythmogenic foods - A growing medical problem. <i>Trends in Cardiovascular Medicine</i> , <b>2020</b> , 30, 310-313	6.9	7
191	Summary of Torsades de Pointes (TdP) Reports Associated with Intravenous Drug Formulations Containing the Preservative Chlorobutanol. <i>Drug Safety</i> , <b>2019</b> , 42, 907-913	5.1	2
190	CredibleMeds.org: What does it offer?. <i>Trends in Cardiovascular Medicine</i> , <b>2018</b> , 28, 94-99	6.9	45
189	Adverse Drug Event Causality Analysis (ADECA): A Process for Evaluating Evidence and Assigning Drugs to Risk Categories for Sudden Death. <i>Drug Safety</i> , <b>2017</b> , 40, 465-474	5.1	29
188	An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval. <i>Drug Safety</i> , <b>2016</b> , 39, 433-41	5.1	26
187	Medical decision support systems and therapeutics: The role of autopilots. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 99, 161-4	6.1	17
186	Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 67, 1639-1650	15.1	152
185	Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 1756-1764	15.1	50
184	Investigation of potential mechanisms of sex differences in quinidine-induced torsade de pointes risk. <i>Journal of Electrocardiology</i> , <b>2015</b> , 48, 533-8	1.4	11
183	Use of Drugs in Long QT Syndrome Type 3 and Brugada Syndrome. <i>Cardiac Electrophysiology Clinics</i> , <b>2014</b> , 6, 811-817	1.4	1
182	Evolving Global Regulatory Science Through the Voluntary Submission of Data: A 2013 Assessment. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2014</b> , 48, 236-245	1.2	4

181	Assessing cardiovascular drug safety for clinical decision-making. <i>Nature Reviews Cardiology</i> , <b>2013</b> , 10, 330-7	14.8	28
180	One hundred years of drug regulation: where do we go from here?. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2013</b> , 53, 255-73	17.9	6
179	Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics. <i>Europace</i> , <b>2013</b> , 15, 1042-9	3.9	47
178	Regulatory and reimbursement innovation. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 176cm3	17.5	6
177	It is important research, but why is it necessary?. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 93, 297-96.1		
176	Community pharmacy and pharmacist staff call center: assessment of medication safety and effectiveness. <i>Journal of the American Pharmacists Association: JAPhA</i> , <b>2011</b> , 51, 82-9	1.7	2
175	Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs. <i>Clinical Therapeutics</i> , <b>2011</b> , 33, 36-45	3.5	17
174	LCMS Analysis of Sertraline and Its Active Metabolite in Human Serum Using a Silica Column with a Non-Aqueous Polar Mobile Phase. <i>Chromatographia</i> , <b>2011</b> , 73, 749-754	2.1	6
173	Research at the interface of industry, academia and regulatory science. <i>Nature Biotechnology</i> , <b>2010</b> , 28, 432-3	44.5	34
172	Pharmacokinetics/Pharmacodynamics of Antiarrhythmic Drugs. <i>Cardiac Electrophysiology Clinics</i> , <b>2010</b> , 2, 341-358	1.4	2
171	Clarification to the www.qtdrugs.org updated lists. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2009</b> , 18, 423-4	2.6	11
170	The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases. <i>Clinical Pharmacology and Therapeutics</i> , <b>2009</b> , 86, 365-7	6.1	44
169	Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. <i>Clinical Pharmacology and Therapeutics</i> , <b>2009</b> , 86, 425-9	6.1	42
168	Time to replace Bazett's QT-correction. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>2009</b> , 32, 1379-80	1.6	2
167	Potential determinants of prescribers' drug-drug interaction knowledge. <i>Research in Social and Administrative Pharmacy</i> , <b>2008</b> , 4, 355-66	2.9	26
166	Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. <i>Drug Safety</i> , <b>2008</b> , 31, 525-36	5.1	70
165	The FDA critical path initiative and its influence on new drug development. <i>Annual Review of Medicine</i> , <b>2008</b> , 59, 1-12	17.4	327
164	Gender and age differences in medications dispensed from a national chain drugstore. <i>Journal of Womens Health</i> , <b>2008</b> , 17, 735-43	3	20

163	They are from the government and they really are here to help you. <i>Journal of Clinical Pharmacology</i> , <b>2008</b> , 48, 142-3	2.9	1
162	Pharmacokinetics of sertraline across pregnancy and postpartum. <i>Journal of Clinical Psychopharmacology</i> , <b>2008</b> , 28, 646-53	1.7	46
161	The translational path includes the FDA's critical path. <i>Journal of Cardiovascular Translational Research</i> , <b>2008</b> , 1, 188-9	3.3	
160	Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects. <i>British Journal of Clinical Pharmacology</i> , <b>2007</b> , 63, 206-15	3.8	36
159	Potential drug-drug interactions within Veterans Affairs medical centers. <i>American Journal of Health-System Pharmacy</i> , <b>2007</b> , 64, 1500-5	2.2	22
158	Pharmacist workload and pharmacy characteristics associated with the dispensing of potentially clinically important drug-drug interactions. <i>Medical Care</i> , <b>2007</b> , 45, 456-62	3.1	70
157	Development of a comprehensive detection method for medicinal and toxic plant species. <i>American Journal of Botany</i> , <b>2006</b> , 93, 566-74	2.7	17
156	Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2006</b> , 316, 1098-106	4.7	121
155	Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. <i>Heart Rhythm</i> , <b>2006</b> , 3, 1003-7	6.7	123
154	Workload and availability of technology in metropolitan community pharmacies. <i>Journal of the American Pharmacists Association: JAPhA</i> , <b>2006</b> , 46, 154-60	1.7	14
153	Community pharmacy managers' perception of computerized drug-drug interaction alerts. <i>Journal of the American Pharmacists Association: JAPhA</i> , <b>2006</b> , 46, 148-53	1.7	18
152	Use of herbal remedies by diabetic Hispanic women in the southwestern United States. <i>Phytotherapy Research</i> , <b>2006</b> , 20, 250-5	6.7	31
151	Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. <i>Health Services Research</i> , <b>2006</b> , 41, 837-55	3.4	76
150	Correction to Geographic Variation in the Prescription of Schedule II Opioid Analgesics among Outpatients in the United States. <i>Health Services Research</i> , <b>2006</b> , 41, 856-859	3.4	4
149	Brief report: development of a prescription medication information webliography for consumers. <i>Journal of General Internal Medicine</i> , <b>2006</b> , 21, 1313-6	4	10
148	Diagramming patients' views of root causes of adverse drug events in ambulatory care: an online tool for planning education and research. <i>Patient Education and Counseling</i> , <b>2006</b> , 62, 302-15	3.1	23
147	Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs. <i>Annals of Pharmacotherapy</i> , <b>2005</b> , 39, 1785-91	2.9	9
146	QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2005</b> , 14, 747-53	2.6	171

145	Inappropriate prescribing for elderly Americans in a large outpatient population. <i>Archives of Internal Medicine</i> , <b>2004</b> , 164, 1621-5		127
144	Discovering adverse reactions: why does it take so long?. <i>Clinical Pharmacology and Therapeutics</i> , <b>2004</b> , 76, 287-9	6.1	11
143	In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchietomized male rabbits. <i>Cardiovascular Research</i> , <b>2003</b> , 57, 28-36	9.9	115
142	Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. <i>American Journal of Medicine</i> , <b>2003</b> , 114, 135-41	2.4	150
141	QTc interval prolongation associated with intravenous methadone. <i>Pain</i> , <b>2003</b> , 105, 499-506	8	166
140	The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. <i>British Journal of Clinical Pharmacology</i> , <b>2002</b> , 53, 519-25	3.8	30
139	Centers for education and research on therapeutics report: survey of medication errors education during undergraduate and graduate medical education in the United States. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 71, 4-10	6.1	15
138	Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2002</b> , 303, 688-94	4.7	201
137	Testosterone-mediated modulation of HERG blockade by proarrhythmic agents. <i>Biochemical Pharmacology</i> , <b>2001</b> , 62, 41-9	6	46
136	Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient. <i>Journal of Clinical Pharmacology</i> , <b>2001</b> , 41, 224-7	2.9	27
135	The role of Internet-based registries in tandem with genetic screening for the study of drug-induced arrhythmias. <i>Current Therapeutic Research</i> , <b>2001</b> , 62, 787-795	2.4	2
134	Relationships between psychotropic drug dosage, plasma drug concentration, and prolactin levels in nursing home residents. <i>Therapeutic Drug Monitoring</i> , <b>2000</b> , 22, 688-94	3.2	3
133	Determination of clemastine in human plasma by gas chromatography with nitrogen-phosphorus detection. <i>Biomedical Applications</i> , <b>2000</b> , 744, 177-81		13
132	Assessment and reporting of clinical pharmacology information in drug labeling. <i>Clinical Pharmacology and Therapeutics</i> , <b>2000</b> , 67, 196-200	6.1	21
131	Greater quinidine-induced QTc interval prolongation in women. <i>Clinical Pharmacology and Therapeutics</i> , <b>2000</b> , 67, 413-8	6.1	110
130	Mechanism of cardiotoxicity of halofantrine. <i>Clinical Pharmacology and Therapeutics</i> , <b>2000</b> , 67, 521-9	6.1	61
129	Biological sex analysis in clinical research. <i>Journal of Women's Health and Gender-Based Medicine</i> , <b>2000</b> , 9, 933-4		3
128	Drug labeling revisions-guaranteed to fail?. <i>JAMA - Journal of the American Medical Association</i> , <b>2000</b> , 284, 3047-9	27.4	33

127	Gadolinium decreases stretch-induced vulnerability to atrial fibrillation. <i>Circulation</i> , <b>2000</b> , 101, 2200-5	16.7	159
126	Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects. <i>Clinical Pharmacology and Therapeutics</i> , <b>1999</b> , 66, 91-9	6.1	21
125	Regulating manufacturer-affiliated communication in the information age. <i>Clinical Pharmacology and Therapeutics</i> , <b>1999</b> , 65, 593-7	6.1	
124	Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. <i>Archives of Internal Medicine</i> , <b>1999</b> , 159, 1733-40		78
123	Female gender is a risk factor for torsades de pointes in an in vitro animal model. <i>Journal of Cardiovascular Pharmacology</i> , <b>1999</b> , 34, 287-94	3.1	55
122	Adenosine A1-receptor occupancy predicts A1-receptor antagonist effects of N-0861. <i>Clinical Pharmacology and Therapeutics</i> , <b>1998</b> , 64, 536-41	6.1	3
121	I.V. Amiodarone: What Do We Really Know About It?. <i>Journal of Interventional Cardiac Electrophysiology</i> , <b>1998</b> , 2, 61-63		
120	Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. <i>Journal of Womens Health</i> , <b>1998</b> , 7, 547-57		160
119	Cardiac actions of erythromycin: influence of female sex. <i>JAMA - Journal of the American Medical Association</i> , <b>1998</b> , 280, 1774-6	27.4	151
118	From bench to bedside: role of gender-based therapeutics in the clinical care of women. <i>Journal of Womens Health</i> , <b>1998</b> , 7, 21-3		4
117	Making medicines safer--the need for an independent drug safety board. <i>New England Journal of Medicine</i> , <b>1998</b> , 339, 1851-4	59.2	107
116	Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. <i>Journal of Clinical Psychopharmacology</i> , <b>1998</b> , 18, 477-81	1.7	99
115	Is dispersion of ventricular repolarization rate dependent?. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>1997</b> , 20, 2405-11	1.6	43
114	Electrophysiologic features of torsades de pointes: insights from a new isolated rabbit heart model. <i>Journal of Cardiovascular Electrophysiology</i> , <b>1997</b> , 8, 1148-58	2.7	82
113	Differential effects of D-sotalol, quinidine, and amiodarone on dispersion of ventricular repolarization in the isolated rabbit heart. <i>Journal of Cardiovascular Electrophysiology</i> , <b>1997</b> , 8, 1239-45	2.7	44
112	Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. <i>Journal of the American College of Cardiology</i> , <b>1996</b> , 27, 67-75	15.1	148
111	Longitudinal prescribing patterns of psychotropic drugs in nursing home residents.. <i>Experimental and Clinical Psychopharmacology</i> , <b>1996</b> , 4, 224-233	3.2	4
110	Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. <i>Clinical Pharmacology and Therapeutics</i> , <b>1996</b> , 59, 383-8	6.1	143

109	Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis. <i>Clinical Pharmacology and Therapeutics</i> , <b>1996</b> , 59, 411-7	6.1	8
108	Message from the Government Affairs Committee. <i>Clinical Pharmacology and Therapeutics</i> , <b>1996</b> , 59, 486-488	6.1	
107	Survey of clinical pharmacology training in the United States and Canada. <i>Clinical Pharmacology and Therapeutics</i> , <b>1996</b> , 60, 1-7	6.1	5
106	Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. <i>Circulation</i> , <b>1996</b> , 94, 1471-4	16.7	262
105	Amiodarone-induced lymphocyte toxicity and mitochondrial function. <i>Journal of Cardiovascular Pharmacology</i> , <b>1996</b> , 28, 94-100	3.1	17
104	Terfenadine increases the QT interval in isolated guinea pig heart. <i>Journal of Cardiovascular Pharmacology</i> , <b>1995</b> , 25, 30-4	3.1	41
103	S-mephenytoin hydroxylation phenotypes in a Jordanian population. <i>Clinical Pharmacology and Therapeutics</i> , <b>1995</b> , 58, 542-7	6.1	14
102	Chlorpheniramine plasma concentration and histamine H1-receptor occupancy. <i>Clinical Pharmacology and Therapeutics</i> , <b>1995</b> , 58, 210-20	6.1	29
101	The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. <i>Clinical Pharmacology and Therapeutics</i> , <b>1995</b> , 57, 662-9	6.1	138
100	Analysis of potential adverse drug reactions--a case of mistaken identity. <i>American Journal of Cardiology</i> , <b>1994</b> , 74, 208-9	3	16
99	The electrocardiographic effects of cetirizine in normal subjects. <i>Clinical Pharmacology and Therapeutics</i> , <b>1994</b> , 56, 295-301	6.1	55
98	Centers for education and research in therapeutics. <i>Clinical Pharmacology and Therapeutics</i> , <b>1994</b> , 55, 249-55	6.1	28
97	Sotalol. <i>New England Journal of Medicine</i> , <b>1994</b> , 331, 31-8	59.2	164
96	New insights into the definition and meaning of proarrhythmia during initiation of antiarrhythmic drug therapy from the Cardiac Arrhythmia Suppression Trial and its pilot study. The CAST and CAPS Investigators. <i>Journal of the American College of Cardiology</i> , <b>1994</b> , 23, 1130-40	15.1	16
95	Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome. <i>Clinical Pharmacology and Therapeutics</i> , <b>1994</b> , 56, 398-405	6.1	28
94	Mechanism of the Cardiotoxic Actions of Terfenadine. <i>JAMA - Journal of the American Medical Association</i> , <b>1993</b> , 269, 1532	27.4	379
93	N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. <i>Carcinogenesis</i> , <b>1993</b> , 14, 675-8	4.6	109
92	Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. <i>Pharmacogenetics and Genomics</i> , <b>1993</b> , 3, 250-5		48

91	Relationship of CYP2D6 (debrisoquine hydroxylase) genotype to breast cancer susceptibility. <i>Pharmacogenetics and Genomics</i> , <b>1993</b> , 3, 322-7		20
90	Immediate- versus controlled-release disopyramide: importance of saturable binding. <i>Clinical Pharmacology and Therapeutics</i> , <b>1993</b> , 54, 16-22	6.1	5
89	d-sotalol reduces heart rate in vivo through a beta-adrenergic receptor-independent mechanism. <i>Clinical Pharmacology and Therapeutics</i> , <b>1993</b> , 53, 436-42	6.1	14
88	QT interval: a measure of drug action. <i>American Journal of Cardiology</i> , <b>1993</b> , 72, 36B-43B	3	41
87	The Integration of Pharmacodynamics and Pharmacokinetics in Rational Drug Development <b>1993</b> , 225-238		2
86	Clinical implications of variable antiarrhythmic drug metabolism. <i>Pharmacogenetics and Genomics</i> , <b>1992</b> , 2, 2-11		32
85	Prognostic significance of ventricular premature depolarizations measured 1 year after myocardial infarction in patients with early postinfarction asymptomatic ventricular arrhythmia. <i>Journal of the American College of Cardiology</i> , <b>1992</b> , 20, 259-64	15.1	30
84	The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. <i>Journal of the American College of Cardiology</i> , <b>1992</b> , 19, 894-8	15.1	113
83	Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. <i>Clinical Pharmacology and Therapeutics</i> , <b>1992</b> , 52, 231-8	6.1	319
82	The clinical value of FDA class C drugs approved from 1981 to 1988. <i>Clinical Pharmacology and Therapeutics</i> , <b>1992</b> , 52, 577-82	6.1	10
81	Prospective pharmacokinetically based development of effective infusion regimens for ACC-9358, a new antiarrhythmic drug. <i>Clinical Pharmacology and Therapeutics</i> , <b>1991</b> , 49, 314-21	6.1	1
80	Salivary analysis for determination of dextromethorphan metabolic phenotype. <i>Clinical Pharmacology and Therapeutics</i> , <b>1991</b> , 49, 410-9	6.1	49
79	Pentamidine-induced torsades de pointes: safe completion of therapy with inhaled pentamidine. <i>Clinical Pharmacology and Therapeutics</i> , <b>1991</b> , 49, 698-700	6.1	17
78	Lack of triggered automaticity despite repolarization abnormalities due to bepridil and lidoflazine. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>1990</b> , 13, 30-6	1.6	10
77	CAST: implications for drug development. <i>Clinical Pharmacology and Therapeutics</i> , <b>1990</b> , 47, 553-6	6.1	12
76	Clinical pharmacokinetics of moricizine. <i>American Journal of Cardiology</i> , <b>1990</b> , 65, 21D-25D; discussion 68D-71D	3	14
75	Efficacy and safety of ACC-9358, a new antiarrhythmic agent. <i>American Journal of Cardiology</i> , <b>1990</b> , 65, 932-4	3	
74	The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. <i>New England Journal of Medicine</i> , <b>1990</b> , 322, 1764-8	59.2	133



73	Relation between ventricular function and antiarrhythmic responses to sotalol. <i>American Journal of Cardiology</i> , <b>1989</b> , 64, 943-5	3	17
72	Recainam dose titration and pharmacokinetics in patients with resistant arrhythmias. <i>Clinical Pharmacology and Therapeutics</i> , <b>1989</b> , 46, 324-34	6.1	5
71	Mexiletine and tocainide: a comparison of antiarrhythmic efficacy, adverse effects, and predictive value of lidocaine testing. <i>Clinical Pharmacology and Therapeutics</i> , <b>1989</b> , 45, 553-61	6.1	17
70	Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans. <i>Journal of Cardiovascular Pharmacology</i> , <b>1989</b> , 14, 364-73	3.1	16
69	The development and testing of intravenous dosing regimens: application to flecainide for the suppression of ventricular arrhythmias. <i>Clinical Pharmacology and Therapeutics</i> , <b>1988</b> , 43, 499-508	6.1	7
68	Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes. <i>Clinical Pharmacology and Therapeutics</i> , <b>1988</b> , 43, 636-42	6.1	51
67	Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease. <i>American Journal of Cardiology</i> , <b>1988</b> , 61, 1006-11	3	30
66	Role of plasma concentration monitoring in the evaluation of response to antiarrhythmic drugs. <i>American Journal of Cardiology</i> , <b>1988</b> , 62, 9H-17H	3	11
65	Overview of the clinical pharmacology of antiarrhythmic drugs. <i>American Journal of Cardiology</i> , <b>1988</b> , 61, 61A-69A	3	17
64	Tocainide plus quinidine for treatment of ventricular arrhythmias. <i>American Journal of Cardiology</i> , <b>1988</b> , 61, 570-3	3	11
63	Clinical pharmacokinetics of encainide. <i>Clinical Pharmacokinetics</i> , <b>1988</b> , 14, 141-7	6.2	10
62	Teaching objectives for fellowship programs in clinical electrophysiology. <i>Journal of the American College of Cardiology</i> , <b>1988</b> , 12, 255-61	15.1	13
61	Indications for antiarrhythmic therapy: a wealth of controversy, a dearth of data. <i>Annals of Internal Medicine</i> , <b>1988</b> , 108, 450-2	8	11
60	Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failure. <i>American Heart Journal</i> , <b>1987</b> , 114, 1280-91	4.9	37
59	Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugs. <i>American Journal of Cardiology</i> , <b>1987</b> , 59, 19E-25E	3	23
58	Proarrhythmia, arrhythmogenesis or aggravation of arrhythmia—a status report, 1987. <i>American Journal of Cardiology</i> , <b>1987</b> , 59, 54E-56E	3	35
57	Pharmacokinetics of moricizine HCl. <i>American Journal of Cardiology</i> , <b>1987</b> , 60, 35F-39F	3	22
56	Indications for different modes of surgical therapy in medically refractory ventricular arrhythmias. <i>Annals of Surgery</i> , <b>1986</b> , 203, 679-84	7.8	8

55	Further evidence for the lack of association between acetylator phenotype and systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1986</b> , 29, 508-14		21
54	Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1986</b> , 29, 843-50		49
53	Encainide disposition in patients with renal failure. <i>Clinical Pharmacology and Therapeutics</i> , <b>1986</b> , 40, 64-70	6.1	24
52	Encainide disposition in patients with chronic cirrhosis. <i>Clinical Pharmacology and Therapeutics</i> , <b>1986</b> , 40, 148-54	6.1	20
51	Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. <i>Clinical Pharmacology and Therapeutics</i> , <b>1986</b> , 39, 282-7	6.1	63
50	Drug therapy. Tocainide. <i>New England Journal of Medicine</i> , <b>1986</b> , 315, 41-5	59.2	68
49	Drug therapy. Flecainide. <i>New England Journal of Medicine</i> , <b>1986</b> , 315, 36-41	59.2	153
48	Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. <i>American Heart Journal</i> , <b>1986</b> , 111, 1088-93	4.9	432
47	Concentration-dependent pharmacologic properties of sotalol. <i>American Journal of Cardiology</i> , <b>1986</b> , 57, 1160-5	3	92
46	Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. <i>American Journal of Cardiology</i> , <b>1986</b> , 57, 25B-33B	3	42
45	Clinical features and basic mechanisms of quinidine-induced arrhythmias. <i>Journal of the American College of Cardiology</i> , <b>1986</b> , 8, 73A-78A	15.1	72
44	Clinical pharmacokinetics of disopyramide. <i>Clinical Pharmacokinetics</i> , <b>1986</b> , 11, 214-22	6.2	30
43	Disposition kinetics of encainide and metabolites. <i>American Journal of Cardiology</i> , <b>1986</b> , 58, 4C-9C	3	29
42	Electropharmacologic synergism with mexiletine and quinidine. <i>Journal of Cardiovascular Pharmacology</i> , <b>1986</b> , 8, 840-6	3.1	10
41	Pharmacokinetics and nondialyzability of mexiletine in renal failure. <i>Clinical Pharmacology and Therapeutics</i> , <b>1985</b> , 37, 649-53	6.1	19
40	QT prolongation and arrhythmia suppression. <i>American Heart Journal</i> , <b>1985</b> , 109, 411-5	4.9	29
39	Bretylium: relations between plasma concentrations and pharmacologic actions in high-frequency ventricular arrhythmias. <i>American Journal of Cardiology</i> , <b>1985</b> , 55, 395-401	3	8
38	Spectrum of antiarrhythmic response to encainide. <i>American Journal of Cardiology</i> , <b>1985</b> , 56, 887-91	3	31

37	Electrophysiology of O-demethyl encainide in a canine model of sustained ventricular tachycardia. <i>Journal of Cardiovascular Pharmacology</i> , <b>1984</b> , 6, 588-95	3.1	12
36	Potential applications of free drug level monitoring in cardiovascular therapy. <i>Clinical Pharmacokinetics</i> , <b>1984</b> , 9 Suppl 1, 79-83	6.2	10
35	Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations. <i>American Journal of Cardiology</i> , <b>1984</b> , 54, 9D-12D	3	61
34	Molecular basis for the antigenicity of lidocaine analogs: tocainide and mexiletine. <i>American Heart Journal</i> , <b>1984</b> , 107, 585-9	4.9	14
33	Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog. <i>American Journal of Cardiology</i> , <b>1984</b> , 54, 654-8	3	28
32	Flecainide dose-response relations in stable ventricular arrhythmias. <i>American Journal of Cardiology</i> , <b>1984</b> , 53, 59B-65B	3	28
31	Clinical importance of metabolites of antiarrhythmic drugs. <i>American Journal of Cardiology</i> , <b>1984</b> , 53, 248-51	3	11
30	Antiarrhythmic therapy: clinical pharmacology update. <i>Journal of Clinical Pharmacology</i> , <b>1984</b> , 24, 295-305	9	2
29	The antiarrhythmic activity of meobentine sulfate in man. <i>Journal of Cardiovascular Pharmacology</i> , <b>1984</b> , 6, 650-6	3.1	7
28	Amiodarone dosing: a proposal based on its pharmacokinetics. <i>American Heart Journal</i> , <b>1983</b> , 106, 951-6	4.9	76
27	Importance of metabolites in antiarrhythmic therapy. <i>American Journal of Cardiology</i> , <b>1983</b> , 52, 3C-7C	3	15
26	Electrophysiologic actions of high plasma concentrations of propranolol in human subjects. <i>Journal of the American College of Cardiology</i> , <b>1983</b> , 2, 1134-40	15.1	44
25	Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide, disopyramide		15
24	Administration of prostacyclin prevents ventricular fibrillation following coronary occlusion in conscious dogs. <i>Journal of Cardiovascular Pharmacology</i> , <b>1982</b> , 4, 765-9	3.1	38
23	Pharmacologic reversal of hypotensive effect complicating antiarrhythmic therapy with bretylium. <i>Clinical Pharmacology and Therapeutics</i> , <b>1982</b> , 32, 313-21	6.1	13
22	Antiarrhythmic effects of the quaternary propranolol analog that does not induce beta-adrenergic blockade. <i>Clinical Pharmacology and Therapeutics</i> , <b>1982</b> , 32, 33-40	6.1	2
21	Selection of an antiarrhythmic drug for a sudden-death-prevention trial. <i>American Heart Journal</i> , <b>1982</b> , 103, 737-45	4.9	7
20	Comparison of the effects of placebo and encainide on programmed electrical stimulation and ventricular arrhythmia frequency. <i>American Journal of Cardiology</i> , <b>1982</b> , 50, 305-12	3	24

19	Control of ventricular preexcitation and associated arrhythmias by encainide. <i>American Heart Journal</i> , <b>1981</b> , 102, 794-7	4.9	10
18	Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. <i>American Journal of Cardiology</i> , <b>1981</b> , 48, 1133-40	3	146
17	Mexiletine for resistant ventricular tachycardia: Comparison with lidocaine and enhancement of efficacy by combination with quinidine. <i>American Journal of Cardiology</i> , <b>1981</b> , 47, 438	3	2
16	Acetylator phenotype and lupus erythematosus. <i>Clinical Pharmacokinetics</i> , <b>1981</b> , 6, 118-34	6.2	52
15	Recurrent ventricular tachycardia in the absence of overt heart disease: clinical characteristics and response to drug therapy. <i>Southern Medical Journal</i> , <b>1981</b> , 74, 1090-4	0.6	5
14	Effects of concentration and steric configuration of propranolol on AV conduction and ventricular repolarization in the dog. <i>Journal of Cardiovascular Pharmacology</i> , <b>1981</b> , 3, 692-703	3.1	8
13	The implications of procainamide metabolism to its induction of lupus. <i>Arthritis and Rheumatism</i> , <b>1981</b> , 24, 994-1003		19
12	Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics. <i>New England Journal of Medicine</i> , <b>1980</b> , 302, 877-82	59.2	174
11	Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. <i>American Journal of Cardiology</i> , <b>1980</b> , 46, 463-8	3	151
10	Evidence for the biotransformation of procainamide to a reactive metabolite. <i>Toxicology and Applied Pharmacology</i> , <b>1979</b> , 50, 9-16	4.6	15
9	Agranulocytosis during combined procainamide and phenytoin therapy. <i>Southern Medical Journal</i> , <b>1979</b> , 72, 1599-601	0.6	10
8	Normal distribution of acetylation phenotypes in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1978</b> , 21, 192-5		27
7	Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. <i>New England Journal of Medicine</i> , <b>1978</b> , 298, 1157-9	59.2	349
6	Pharmacokinetics of antiarrhythmic drugs. <i>American Journal of Cardiology</i> , <b>1978</b> , 41, 986-95	3	45
5	Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function. <i>Clinical Pharmacology and Therapeutics</i> , <b>1977</b> , 22, 63-9	6.1	71
4	Antiarrhythmic effects of a lidocaine congener, tocainide, 2-amino-2',6'-propionoxylidide, in man. <i>Clinical Pharmacology and Therapeutics</i> , <b>1976</b> , 19, 396-402	6.1	83
3	Guanethidine. <i>New England Journal of Medicine</i> , <b>1976</b> , 295, 1053-7	59.2	50
2	Metabolism of L-methionine- 35 S in zinc-deficient rats. <i>Journal of Nutrition</i> , <b>1972</b> , 102, 1181-6	4.1	8

- 1 An Information Technology Architecture for Drug Effectiveness Reporting and Post-Marketing Surveillance 131-145